Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17744
Country/Region: Nigeria
Year: 2016
Main Partner: Excellence Community Education Welfare Scheme
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $950,622 Additional Pipeline Funding: $130,721

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $82,865
Care: Orphans and Vulnerable Children (HKID) $26,138
Care: TB/HIV (HVTB) $81,423
Care: Pediatric Care and Support (PDCS) $93,840
Laboratory Infrastructure (HLAB) $0
Testing: HIV Testing and Counseling (HVCT) $148
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $426,078
Treatment: Adult Treatment (HTXS) $226,204
Treatment: Pediatric Treatment (PDTX) $13,926
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 28
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 6
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 32
GEND_GBV Number of people receiving post-GBV care 2017 38
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,514
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,343
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 96,330
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 10,751
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 109,938
HTS_TST Service Delivery Point (Facility): Index testing 2017 55
HTS_TST Service Delivery Point (Facility): Inpatient 2017 55
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 29
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2
HTS_TST Service Delivery Point (Facility): Outpatient 2017 16,052
HTS_TST Service Delivery Point (Facility): Pediatric 2017 2,857
HTS_TST Service Delivery Point (Facility): PMTCT 2017 84,206
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 662
HTS_TST Service Delivery Point (Facility): VCT 2017 6,020
HTS_TST Sum of Aggregated Age/Sex <15 2017 2,857
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 107,081
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 109,938
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 11
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 8
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 787
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 91
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 8
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 9
LAB_PT CD4: Number of laboratories that perform this testing 2017 9
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 8
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 9
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 9
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 344
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 319
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 663
PMTCT_ART Already on ART at beginning of current pregnancy 2017 394
PMTCT_ART New on ART 2017 606
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 83,809
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 587
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 413
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 11
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 3
PMTCT_EID Sum of Infant Age disaggregates 2017 1,000
PMTCT_STAT By: Known positives at entry 2017 436
PMTCT_STAT By: Number of new positives identified 2017 654
PMTCT_STAT Number of new ANC and L&D clients 2017 88,605
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 83,809
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,090
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 44
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 37
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 755
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 84
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 73
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 66
TB_SCREENDX Screen Result: Screened Positive for TB 2017 82
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 2,764
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 688
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 53
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 20
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 3,525
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 15
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 320
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 157
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 499
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 554
TX_CURR Aggregated Age/Sex: <15 Female 2017 68
TX_CURR Aggregated Age/Sex: <15 Male 2017 74
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,292
TX_CURR Aggregated Age/Sex: 15+ Male 2017 925
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 3,359
TX_CURR Sum of Aggregated Age/Sex <15 2017 142
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 3,217
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 3,359
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 12
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 9
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 632
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 559
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,212
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,212
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 3,235
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 3,565
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 108
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 117
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,386
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 954
TX_PVLS Numerator: Indication: Routine 2017 2,852
TX_PVLS Numerator: Indication: Targeted 2017 713
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 93
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 98
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 2,173
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 871
TX_PVLS_den Denominator: Indication: Routine 2017 2,588
TX_PVLS_den Denominator: Indication: Targeted 2017 647
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 31
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 36
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 599
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 218
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 884
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 1,040
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 37
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 42
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 702
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 259
Cross Cutting Budget Categories and Known Amounts Total: $147,759
Human Resources for Health $104,824
Economic Strengthening $10,000
Gender: Gender Based Violence (GBV) $5,358
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $24,389
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Food and Nutrition: Commodities $3,188